MetLife Investment Management’s Lyell Immunopharma LYEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-1,814
| Closed | -$50.1K | – | 2838 |
|
|
2024
Q3 | $50.1K | Sell |
1,814
-2,459
| -58% | -$67.9K | ﹤0.01% | 2754 |
|
|
2024
Q2 | $124K | Sell |
4,273
-282
| -6% | -$8.18K | ﹤0.01% | 2492 |
|
|
2024
Q1 | $203K | Sell |
4,555
-50
| -1% | -$2.23K | ﹤0.01% | 2195 |
|
|
2023
Q4 | $179K | Hold |
4,605
| – | – | ﹤0.01% | 2296 |
|
|
2023
Q3 | $135K | Hold |
4,605
| – | – | ﹤0.01% | 2424 |
|
|
2023
Q2 | $293K | Buy |
4,605
+854
| +23% | +$54.3K | ﹤0.01% | 2029 |
|
|
2023
Q1 | $177K | Sell |
3,751
-874
| -19% | -$41.2K | ﹤0.01% | 2289 |
|
|
2022
Q4 | $321K | Hold |
4,625
| – | – | ﹤0.01% | 1928 |
|
|
2022
Q3 | $678K | Hold |
4,625
| – | – | 0.01% | 1417 |
|
|
2022
Q2 | $603K | Buy |
4,625
+399
| +9% | +$52K | ﹤0.01% | 1532 |
|
|
2022
Q1 | $427K | Buy |
+4,226
| New | +$427K | ﹤0.01% | 1867 |
|
|
2021
Q4 | – | Sell |
-516
| Closed | -$153K | – | 2529 |
|
|
2021
Q3 | $153K | Buy |
+516
| New | +$153K | ﹤0.01% | 2247 |
|